VA-REGULA
15.2.2024 08:01:33 CET | Business Wire | Press release
Frost & Sullivan recognizes companies with Best Practices Awards in various categories for outstanding efforts to inspire growth in their industries. Businesses that earn these awards identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. Frost & Sullivan considers these companies to be the game changers.
As for the Enabling Technology Leadership Award in the identity verification (IDV) industry, Frost & Sullivan applies a rigorous analytical process to assess multiple nominees. This involves a detailed evaluation of best practices criteria across two dimensions: Technology Leverage and Customer Impact. Frost & Sullivan points out that Regula excels in many of the criteria in the IDV solutions space.
Synergizing cutting-edge verification technologies with an intuitive user-centric design. Experts emphasize Regula's product portfolio, seamlessly integrating a single-vendor solution for complete identity verification based on biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with enhanced authenticity validation, along with forensic devices dedicated to in-depth examination. At the heart of Regula’s IDV solution lies the most comprehensive database encompassing over 13,500 documents from 247 countries and territories, supporting over 138 languages.
Regula distinguishes itself by fostering innovation through in-house development of all technologies, steering clear of third-party dependencies. Notably, its standout feature is the platform-agnostic nature of its digital identification solutions. This enables customers to orchestrate an enhanced ID verification process effortlessly on any platform—be it mobile, web, desktop platforms, or passport readers.
Forging strategic alliances with renowned international organizations. Regula forges strategic partnerships with esteemed organizations like the International Air Transport Association, International Organization for Migration, and International Civil Aviation Organization. This collaborative effort establishes Regula as an integral player in a symbiotic exchange of insights and vital information about documents. This ongoing collaboration serves as a catalyst for continuously refining its technologies, positioning the company at the forefront of innovation.
Transforming customer workflows in many industries through value-driven verification solutions. Regula's distinctive offering lies in its rich heritage in the forensics space. The one-stop-shop nature of Regula’s solutions eradicates the necessity for customers to enlist multiple vendors for additional security measures and ensures a comprehensive strategy addressing security, forensics, and identity verification requirements in a seamless and integrated manner.
Enduring excellence through long-term customer relationships. Regula’s value-driven identity verification solutions extend across a spectrum of industry verticals, including banking, fintech, aviation, telecommunication, government authorities, healthcare, insurance, forensic labs, gambling, and others. The company's achievements are evidenced by providing hardware and software solutions for digital identity verification to a global network of over 1,000 organizations and 80 border control authorities. Notably, Regula's clientele includes major players such as the largest private bank globally, and prominent airline companies like AirAsia and WizzAir. Also, Regula has solidified its position as a trusted technology partner for several years at the Mobile World Congress (MWC), a premier international industry event organized by the GSMA.
On top of this, Frost & Sullivan believes Regula outperforms in responding to the complex landscape of identity fraud. Rabin Dhakal, Frost & Sullivan Best Practices Research Analyst states: “In the face of an escalating wave of sophisticated fraud, identity theft, and scams, the urgency for a robust identity verification solution has never been more pronounced. Frost & Sullivan believes that Regula’s proactive response to the evolving landscape of document fraud and fakes is unprecedented.”
"We are truly honored to be acknowledged by a prominent expert in market growth and innovations. We strive to emphasize the key differentiator for Regula, which lies in the wealth of experience gained over three decades - specifically in understanding documents and verification processes, our comprehensive document template database, full-cycle in-house production, and the team of top-notch forensic experts. These are the assets that enable us to drive continuous innovation and provide a comprehensive solution to identity verification,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the 2024 Frost & Sullivan Global Enabling Technology Leadership Award in the identity verification solutions industry, please read the report.
About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214825831/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom